Article thumbnail
Location of Repository

The role of proteomics in depression research

By Daniel Martins-de-Souza, Laura W. Harris, Paul C. Guest, Christoph W. Turck and Sabine Bahn

Abstract

Depression is a severe neuropsychiatric disorder affecting approximately 10% of the world population. Despite this, the molecular mechanisms underlying the disorder are still not understood. Novel technologies such as proteomic-based platforms are beginning to offer new insights into this devastating illness, beyond those provided by the standard targeted methodologies. Here, we will show the potential of proteome analyses as a tool to elucidate the pathophysiological mechanisms of depression as well as the discovery of potential diagnostic, therapeutic and disease course biomarkers

Topics: Original Paper
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2940035
Provided by: PubMed Central

Suggested articles

Citations

  1. (2009). 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease.
  2. (2007). 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia.
  3. (2009). A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder.
  4. (2006). A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia.
  5. (2007). Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study.
  6. (2000). Addiction, dopamine, and the molecular mechanisms of memory.
  7. (2007). Adult hippocampal neurogenesis as target for the treatment of depression.
  8. (1992). Alphs LD et al
  9. (2009). Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.
  10. (2009). Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression.
  11. (2009). Altered expression of lipid metabolism and immune response genes in the frontal cortex of suicide completers. J Affect Disord [Epub ahead of print]
  12. (2009). Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy.
  13. Baiker A et al (2003) VEGF is necessary for exercise-induced adult hippocampal neurogenesis.
  14. (2008). Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with longterm quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression.
  15. (2008). Biomarker profiles in serum and saliva of experimental Sjogren’s syndrome: associations with specific autoimmune manifestations.
  16. (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression.
  17. Bunney WE et al (2009) Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression.
  18. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.
  19. (2008). Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.
  20. (2002). Depletion of norepinephrine decreases the proliferation, but does not influence the survival and differentiation, of granule cell progenitors in the adult rat hippocampus.
  21. (2000). Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence.
  22. (2007). Differences in protein profiles in schizophrenia prefrontal cortex compared to other major brain disorders. Clin Schizophrenia Relat Psychoses 1:21–39
  23. (2007). Differentiating antidepressants of the future: efficacy and safety.
  24. (1999). Direct analysis of protein complexes using mass spectrometry.
  25. (2000). Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5:142–149
  26. (2005). DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity.
  27. EA et al (2003) Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice.
  28. Erraji-Benchekroun L et al (2004) Gene expression profiling of depression and suicide in human prefrontal cortex.
  29. (2000). Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology.
  30. (2002). Evidence that brain derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus during contextual learning.
  31. (2007). Fatty acid composition in postmortem brains of people who completed suicide.
  32. (2009). Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry [Epub ahead of print]
  33. Glover A et al (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease.
  34. Gormanns P et al (2010) Proteome analysis of schizophrenia brain tissue.
  35. Gormanns P et al (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers for schizophrenia.
  36. Grenier E et al (2007) Cholesterol content in brains of suicide completers.
  37. (1996). Hippocampal atrophy in recurrent major depression.
  38. Huang JT et al (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress.
  39. Hunyadi-Gulya ´s E et al (2009) Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia.
  40. (2006). Identification of differentiating neural progenitor cell markers using shotgun isobaric tagging mass spectrometry.
  41. (2006). Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis.
  42. (2005). Identification ofglyoxalase-Iasaproteinmarkerinamousemodel of extremes in trait anxiety.
  43. (2000). In vivo investigation of white matter pathology in schizophrenia with magnetization transfer imaging.
  44. (2008). Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues.
  45. Lv FJ et al (2007) Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model.
  46. (2004). Mechanisms of action of the antidepressants fluoxetine and the substance P antagonist L-000760735 are associated with altered neurofilaments and synaptic remodeling.
  47. (2002). Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine.
  48. (2007). Multi-analyte profiling of postmyocardial infarction plasma samples.
  49. (2008). Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
  50. N et al (2006) Disease biomarkers in cerebrospinal fluid of patients with firstonset psychosis.
  51. (2009). Neurobiological mechanisms in major depressive disorder.
  52. (2000). Neuronal plasticity and survival in mood disorders.
  53. (2006). Oligodendrocytes as providers of growth factors.
  54. (2010). Orringer EP et al (2007) Phase I study of eptifibatide in patients with sickle cell anaemia.
  55. (2001). Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.
  56. (2007). Patterns of gene expression in the limbic system of suicides with and without major depression.
  57. (2009). Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia.
  58. (1996). Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it.
  59. (2009). Proteome analysis of schizophrenia patients Wernicke’s area reveals an energy metabolism dysregulation.
  60. (2006). Proteomic analysis identifies alterations in cellular morphology and cell death pathways in mouse brain after chronic corticosterone treatment.
  61. (2009). Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations
  62. (2004). Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies.
  63. (2006). Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes.
  64. (2008). Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia.
  65. (2007). Proteomic investigation of the ventral rat hippocampus links DRP-2 to escitalopram treatment resistance 504 Eur Arch Psychiatry Clin Neurosci
  66. (2007). Proteomics analysis of the Alzheimer’s disease hippocampal proteome.
  67. (2009). Proteomics is not only a biomarker discovery tool.
  68. (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments.
  69. (1999). Serotonin and hippocampal neurogenesis.
  70. (2007). Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex.
  71. Targosz BS et al (2009) Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways. Mol Psychiatry [Epub ahead of print]
  72. (2002). The neuropathology of primary mood disorder.
  73. (1999). Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum.
  74. (2000). Unconditioned anxiety and social behaviour in two rat lines selectively bred for high and low anxiety-related behaviour.
  75. Vawter MP et al (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.
  76. (2001). World Health Organization

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.